Join us to learn the essentials of drug and device law and how to engage with FDA to better support your organization’s advocacy efforts.

For this multi-day virtual program, FDLI brings together law, industry, and FDA experts with deep advocacy experience to equip patient organizations with an understanding of the legal tools and strategies available for interacting with the agency. Case studies will illustrate the opportunities for engagement and legal challenges facing patient organizations.

Agenda Highlights Include:

  • New Drug Development and Clinical Trials Regulation
  • Submission of Marketing Applications and the FDA Approval Process
  • Expanded Access
  • Implementation of the 21st Century Cures Act
  • New Device Development
  • The 510(k) Process and De Novo Review for Devices
  • Interacting with Drug and Device Development Industries and FDA




This course is open to staff and volunteers with a leadership role of 501(c)(3) patient or disease organizations. Applications will be considered on a case by case basis. Registration for this program is $49.

Apply Now

2019 Agenda

Preliminary 2020 agenda coming soon

Tuesday, November 5

8:15 – 8:45 AM
Registration and Continental Breakfast

8:45 – 9:00 AM
Welcome and Announcements

9:00 – 10:00 AM
Introduction to FDA and Other Agencies

David Chesney, Principal and General Manager, DL Chesney Consulting

  • The U.S. Drug Regulatory Process
  • FDA Organization
  • Types of FDA Regulatory Requirements and Pronouncements
  • Congressional Oversight
  • The FDA’s Relationship with Other Agencies

10:00 – 11:00 AM
New Drug Development Under an Investigational New Drug Application (IND)

Heidi Gertner, Partner, Hogan Lovells US LLP

  • What is a “Drug”?
  • What is a “New Drug”?
  • Other Drug-Like Products
  • Who Decides Whether a Product is a “New Drug”?
  • The IND Process
  • IND Application

11:00 – 11:15 PM
Networking Break

 11:15 AM – 12:45 PM

Approval and Clearance Pathways for Medical Devices

Jeffrey Gibbs, Director, Hyman, Phelps & McNamara, PC

  • What is a “Device”?
  • Medical Device Amendments of 1976
  • Predicate Devices and Substantial Equivalence
  • Who Decides Whether a Device Needs Premarket Approval (PMA) or a 510(k) Clearance?
  • Laboratory-Developed Tests and In-Vitro Diagnostics
  • De Novo Requests for Classification

 12:45 – 1:30 PM

1:30 – 3:00 PM
The FDA Approval Process for Drugs

Maureen M. Japha, Counsel, Peterson Wilmarth and Robertson, LLP (PWR)

  • Submission & Filing of NDAs/BLAs
  • Approval Standards
  • The Review Process
  • Expedited Review

3:00 3:15 PM
Networking Break

3:15 – 4:15 PM
Conduct of Clinical Trials for Drugs and Medical Devices and Human Subjects Protections

Kinsey S. (K.S.) Reagan, Partner, Kleinfeld, Kaplan & Becker, LLP

  • Clinical Testing/Investigation and “Good Clinical Practice” (GCP)
  • Clinical Trials Registration and Results Reporting (
  • Human Subjects Research Protection
  • Bioresearch Monitoring (BIMO)
  • Investigational Device Exemptions
  • Adverse Event Reporting

4:15 – 5:00 PM
Stakeholder Interactions in the Drug Development Community

Debra Lappin, Principal and Lead, Health & Biosciences Team, Faegre Baker Daniels Consulting

  • Sponsor-Patient Group Engagement
  • Payor Communications Post-Cures Act

5:00 – 6:00 PM

Wednesday, November 6

8:30 – 9:00 AM
Continental Breakfast

9:00 – 10:00 AM
Expanded Access to Investigational Therapies for Drugs and Medical Devices

Richard Klein, Director, Expanded Access Programs & Policy, GE2P2 Global Foundation

  • Expanded Access
  • Federal Right-to-Try Legislation and Effect on Current FDA Expanded Access Framework

10:00 – 11:00 AM
Post-Approval Obligations of Drug Companies

Cecilia Bakker, Assistant General Counsel, Regulatory Law, Pfizer, Inc.

  • Post-Approval (“Phase IV”) Investigations
  • Withdrawal of Approval
  • Annual Reports
  • Adverse Drug Experience (ADE) Reports
  • Post-Approval Changes and Supplemental NDAs (sNDAs) and ANDAs
  • Grounds for Withdrawal of Approval
  • Sale/Transfer of NDAs/ANDAs
  • Post-Approval Safety Issues
  • Product Quality Considerations
  • Unapproved Uses of Drugs

11:00 – 11:15 AM
Networking Break

11:15 AM – 12:15 PM
Post-Marketing Issues for Medical Device Companies

Stephanie Philbin, Partner, Goodwin Procter, LLP

  • Adverse Event Reporting Procedures 
  • Product Recalls
  • Product Servicing and Refurbishing
  • Unique Device Identifiers
  • Safety Alerts and Physician Communication
  • Ongoing Monitoring of Device Performance and Conditions of a PMA

12:15 – 1:00 PM

1:00 – 2:00 PM
Hatch-Waxman and Other Statutory Incentives

Daniel Orr, Partner, Womble Bond Dickinson (US) LLP

  • Patent Term Restoration/Extension
  • Five- and Three-Year Exclusivity
  • 180-Day Exclusivity
  • Pediatric Exclusivity
  • Orphan Drugs
  • Priority Review Vouchers (PRVs) (Tropical Disease, Rare Pediatric Disease, and Medical Countermeasures)
  • Biosimilars: Intersection of Regulatory Exclusivity and Patent Exclusivity

2:00 – 2:15 PM  
Networking Break

2:15 – 3:15 PM
Engaging with FDA: Opportunities and Boundaries

Eleni Anagnostiadis, Director, Professional Affairs and Stakeholder Engagement, Center for Drug Evaluation and Research (CDER), FDA
Andrea Furia-Helms, Director, Patient Affairs Staff, Office of the Commissioner, FDA
Michelle Tarver, Director, Patient Science and Engagement, Center for Devices and Radiological Health (CDRH), FDA

  • FDA’s Patient Engagement Offices
  • FDA’s Patient Engagement Programs
  • Participating in FDA Policymaking

3:15 – 4:00 PM
Tying it All Together: Engaging with FDA to Improve Advocacy Outcomes

Ryan Hohman, Vice President, Public Affairs, Friends of Cancer Research
Richard Klein, Director, Expanded Access Programs & Policy, GE2P2 Global Foundation
Debra Lappin, Principal and Lead, Health & Biosciences Team, Faegre Baker Daniels Consulting
Moderated by Paige Samson, Director, Innovative Programs and Publications, Food and Drug Law Institute

This session will highlight relevant case studies of how effective advocacy and utilizing the knowledge gained from this course can have an impact on FDA policymaking.

4:00 PM

A Special Thanks to the FDLI Patient Organization Engagement Committee

Ryan Hohman, Friends of Cancer Research
Kristin Schneeman, FasterCures
Maureen M. Japha, Eli Lilly and Company
Debra Lappin, Faegre Drinker Biddle & Reath LLP
Katherine Maynard, Peterson Wilmarth and Robertson, LLP (PWR)
Lisa Pieretti, International Hyperhidrosis Society
Ami E. Simunovich, Becton Dickinson (BD)
James Valentine, Hyman, Phelps & McNamara, PC
Laura D. Wingate, Crohn’s & Colitis Foundation


Sponsorship opportunities are available. Please let us know if you would like more information.